South China Venture Capital

YoungEn Technology is a manufacturing company that specializes in automated production equipment. It primarily focuses on developing and producing advanced MiniLED sorting machines for the display industry, offering high-quality, innovative solutions to its clients.

Yhope Tech is a high-tech company that designs, researches, develops, consults, and sells solutions for industrial automation, interconnection, and intelligent manufacturing.

Yuewei Medical is a developer of interventional medical devices specifically designed for cardiac surgery. The company focuses on creating innovative solutions that enhance the entire process of medical device development and implementation in this field. Its product portfolio includes devices such as coronary artery bypass graft fixators, intraoperative ultrasonic flow detectors, left ventricular assist devices, and coronary anastomosis auxiliary systems. By providing advanced medical devices, Yuewei Medical aims to contribute significantly to the advancement of cardiac surgery and improve patient outcomes.

Presheng New Materials is a high-end semiconductor polishing solution provider. The company has extensive technical knowledge of high-end abrasives. Prisheng focuses on the research and development of high-end alumina polishing fluids, polishing abrasives, and other goods. Provider of cost-effective local solutions for third-generation compound semiconductor polishing.

Sanhydro Technology focuses on the design, sales, and production of intelligent integrated hydrogen fuel cell stacks molded, graphite bipolar plates.

IDT Micro is a microelectronics technology company that specializes in manufacturing and developing automotive-grade analog chips and power switching devices.

Namei Semiconductor develops semiconductor probe station technology, and its devices are mostly utilized in the CP testing process following wafer manufacturing and prior to packing.

Zentek is a manufacturer of high-end silicone materials used for research and development. The company operates in eight main application areas: automotive electronics, consumer electronics, power batteries, packaging, industry, medical care, semiconductor wafer processing, and chip packaging.

Sanshiyuan Technology is engaged in the R&D, production, and sale of passive optical fiber devices. Its main products include: optical fiber circulators, high-end passive integrated devices, high-reliability, cost-effective wavelength division multiplexers, and high-reliability cost-effective optical fiber isolator, MEMS optical switch, product features are miniaturization and integration.

Avant Semi is a high-tech enterprise specializing in the development and manufacturing of semiconductor front-end measurement and testing equipment. The company produces advanced equipment designed for use in semiconductor production, which can be integrated with ultra-high vacuum systems and specialized chambers. This equipment enables precise measurement of various epitaxial layers, photoresist thickness, and element concentration, allowing semiconductor manufacturing companies to optimize their production processes. By providing reliable measurement solutions, Avant Semi helps its clients reduce operational costs and maintenance efforts in semiconductor fabrication.

Huixin Bio is a researcher and developer of liquid biopsy diagnostic products. It focuses on developing world-leading biomedical technologies and products. It offers an automatic exosome purification system.

Zheta Technology offers high-end manufacturing digital transformation services to help manufacturing companies complete intelligent upgrades, using deeply integrated Big Data, AI algorithms, and industry know-how. Zheta Technology assists customers in increasing yield rate, equipment utilization rate, and production capacity, as well as completing the transparent management of the next generation of digital factories.

Bangxin Semiconductor specializes in manufacturing semiconductor equipment, catering to the integrated circuit and broader semiconductor industries. The company's core focus lies in four key areas: compound semiconductors, integrated circuits, packaging and testing, and panel industries. It continually works on developing new equipment and supporting emerging manufacturing processes for both compound and silicon chip industries.

Liufang Tech specializes in the development and production of silicon carbide (SiC) technology, primarily focusing on its application in the semiconductor industry. The company offers a range of products, including chemical vapor deposition (CVD) silicon carbide coatings, graphite components, and tantalum carbide-coated products. These materials are pivotal in the production of semiconductor chips, particularly in sectors such as LED, SiC, gallium nitride (GaN), and monocrystalline silicon epitaxy. By providing hard and high-temperature resistant materials, Liufang Tech aims to enhance the performance and durability of semiconductor applications for its clients.

Immunowake is a biotechnology company dedicated to developing innovative therapies for patients who do not respond to conventional immunotherapies. The company aims to activate the immune system, specifically targeting antigen-specific T-cells, to enhance the body’s ability to recognize and eliminate cancer cells. By focusing on creating a universal cancer vaccine and bi-specific antibodies, Immunowake seeks to improve treatment outcomes while minimizing toxicity. Its research is rooted in recent advancements in cancer immunotherapy, striving to generate safer and more effective therapeutic options for patients with challenging cancer profiles.

Wuxi Xinxiang is a semiconductor factory production automation CIM solution and services provider. They focus on intelligent automation production solutions and services in the field of wafer manufacturing, packaging and testing.

Accro Bioscience is a biopharmaceutical company that specializes in the development of innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company conducts research on the molecular mechanisms underlying regulated cell death processes, including necroptosis, pyroptosis, and ferroptosis. By understanding these mechanisms, Accro Bioscience aims to enhance current therapeutic approaches and address specific pathologies associated with various human diseases.

Innoforce Pharmaceuticals Co., Ltd is a biopharmaceutical company based in Hangzhou, China, founded in 2018. The company specializes in the development and commercialization of biomedicines and therapies, including cell and gene therapies, medicines, and antibodies. Innoforce operates biologic process development laboratories and offers end-to-end contract development and manufacturing services to support biotech enterprises in their research and development and manufacturing needs. By providing customized product development and operations management, Innoforce enables its clients to effectively bring their biopharmaceutical products to market.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Innoforce Pharmaceuticals Co., Ltd is a biopharmaceutical company based in Hangzhou, China, founded in 2018. The company specializes in the development and commercialization of biomedicines and therapies, including cell and gene therapies, medicines, and antibodies. Innoforce operates biologic process development laboratories and offers end-to-end contract development and manufacturing services to support biotech enterprises in their research and development and manufacturing needs. By providing customized product development and operations management, Innoforce enables its clients to effectively bring their biopharmaceutical products to market.

Cullgen Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics based on its uSMITE platform, which enables targeted protein degradation by using novel E3 ligands to selectively degrade disease-causing proteins. The approach aims to address cancers, inflammatory and autoimmune diseases, and other conditions lacking effective therapies. Founded in 2018 and based in San Diego, Cullgen's pipeline includes degrader programs such as TRK and GSPT1, as well as other candidates like DAC.

Drug Farm Inc. is a biotech company based in Shanghai, China, engaged in the development of innovative drugs and technologies for metabolic diseases such as obesity, diabetes, and fatty liver, as well as targeting innate immunity for conditions like HBV, cancer, and autoimmune diseases. The company employs its unique IDInVivo platform, which integrates advanced genetics and artificial intelligence to identify novel drug targets through genetic screens in living animals with intact immune systems. By leveraging various AI methodologies, including supervised learning, active learning, and reinforcement learning, Drug Farm aims to accelerate the medicinal chemistry development process, ultimately striving to deliver first-in-class therapeutic solutions to the healthcare industry.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

CARsgen Therapeutics, Ltd. is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor T-cell (CAR-T) therapeutics for cancer treatment. Based in Shanghai, China, the company focuses on innovative immunotherapy solutions that harness the body's immune system to target and eliminate cancer cells. CARsgen's CAR-T technology is designed to direct T cells to recognize and attack tumors based on specific cell surface proteins, targeting conditions such as hepatocellular carcinoma (HCC) and lung squamous cell carcinoma, among others. The company has made significant advancements in CAR-T development, including the completion of the world's first dose-ascending injection tests for HCC and exclusive trials for glioblastoma multiforme in China. Through partnerships with notable institutions like the Shanghai Cancer Institute and Shanghai Renji Hospital, CARsgen Therapeutics aims to position itself at the forefront of cancer therapeutics both in China and internationally.

Shanghai Zhuishi Technology Co., Ltd., founded in 2019, specializes in the research and development of low-speed autonomous driving technology. Based in Shanghai, China, the company focuses on creating autonomous driving systems and solutions tailored for automotive manufacturers. Zhuishi Technology aims to advance the capabilities of self-driving vehicles, contributing to the evolution of transportation through innovative technology.

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Ipoweru.cn is an online education platform founded in 2017 and based in Beijing, China. The company specializes in providing personalized education solutions for schools, focusing on recruitment and streaming class videos. It offers a range of online courses designed to prepare students for college entrance examinations. Additionally, Ipoweru.cn supports local education bureaus by assisting with the implementation of the new college entrance examination's multiple admission backgrounds, thereby enhancing the overall educational experience and facilitating better outcomes for students.

EpimAb Biotherapeutics is a privately held biopharmaceutical company based in Shanghai that develops novel bispecific antibody therapeutics, with a focus on immuno-oncology and other high-value indications. The company uses its proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform to generate bispecific molecules that combine antibody-like properties with improved design features, aiming to enhance target binding, pharmacokinetics and manufacturability. Through in-house research and development, EpimAb advances novel bispecific candidates intended to expand treatment options for patients and address remaining challenges in bispecific drug development.

Apollomics is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies that harness the immune system and target specific cancer signaling pathways. Founded in 2016 and headquartered in Foster City, California, the company develops monoclonal antibodies and targeted small molecules aimed at immune checkpoints and dysregulated growth pathways, with a portfolio that includes anti-PD-1 and anti-PD-L1 antibodies and inhibitors affecting EMT and MAPK signaling. Apollomics aims to advance monotherapy and combination regimens designed to enhance anti-tumor immune responses and inhibit tumor growth.

Daily Shakes is a block chain social service platform that provides users with interactive content sharing.

Shenzhen Huahui Technology Co., Ltd. specializes in designing and developing quality management and improvement solutions for enterprises. Founded in 2012 and based in Shenzhen, China, the company offers a range of services in software, information technology, and cloud computing. Huahui Technology provides customized and modular solutions tailored to meet diverse client needs, helping organizations to establish effective quality management systems. Its product offerings include intelligent visualization tools, multi-dimensional data mining, and quality statistical analysis, alongside defect tracking and early warning services. Through its SaaS quality assurance system, the company enables clients to quantify product quality data and generate detailed quality check reports, facilitating systematic management of production processes and assisting enterprises in implementing active quality management strategies.

Wuxian Zhitou focuses on performing time series classification and prediction in ETF and mutual fund markets using the machine learning paradigm.

LEADRIVE is a technology company specializing in the research, development, production, and sales of drive solutions for new energy vehicles, as well as high-performance power semiconductor modules. The company designs and manufactures advanced motor controllers and proprietary power modules that have been adopted by over ten leading automotive manufacturers and Tier-1 suppliers for mass production. LEADRIVE is also engaged in enhancing the localization of power semiconductor modules, with ongoing certification processes for silicon carbide modules and electronic controls. Additionally, the company invests in innovative energy solutions, including wind, solar, and energy storage systems. In collaboration with Rohm Semiconductor from Japan, LEADRIVE has established a joint laboratory to develop various silicon carbide modules, focusing on improving efficiency through comprehensive simulation, testing, and development processes that span from device-level to vehicle-level applications.

Chongxin Chongwu is a professional pet health solutions and service provider.

Tian Jian is a medical technology company that specializes in developing medical information systems and software tailored for hospitals. The company focuses on creating digital solutions that enhance hospital operations, including medical cost management, patient services, and decision-making processes. By providing these innovative tools, Tian Jian enables healthcare facilities to digitize their operations and improve overall efficiency. Additionally, the company addresses customer inquiries through various channels, including phone, email, and online applications, ensuring effective communication and support for its clients in the healthcare sector.

Zhuhai Biyao Technology Co., Ltd. operates an online e-commerce platform that connects consumers directly with quality manufacturers. Founded in 2014 and based in Zhuhai, China, the company offers a diverse range of products including accessories, cosmetics, apparel, furniture, and footwear. Biyao's platform aims to streamline the shopping experience by allowing customers to access high-quality products from renowned designers and manufacturers at factory prices, effectively eliminating intermediaries. This direct-to-consumer approach enhances product availability and affordability for customers.

Shaanxi Xifeng Liquor is a liquor-producing firm. They serve collector's editions: the colorful Xifeng wine series, the sea of wine aging series, the old green bottle series, the six-year and fifteen-year series, the Huashan on Sword series, and the national flower porcelain series. The work's main theme is to insist on putting equal focus on brand promotion and product sales.

sungoal provides exhibition service for new energy automobile and home building materials.